we analyzed outcomes of 13 patients who underwent open surgical debranching of renovisceral vessels for thoracoabdominal aortic aneurysm and PAAAs. All patients were considered at high risk for conventional surgery. Inclusion criterion was treatment by open surgical debranching of at least one visceral artery (renal artery, superior mesenteric artery [SMA], or celiac trunk [CT]) using the GHVG. In a second step, the aortic stent graft was implanted to exclude the aneurysm. If required, parallel grafts to the remaining visceral arteries were deployed in the same procedure. One patient had a symptomatic descending thoracic aortic aneurysm and another had a ruptured PAAA. Perioperative measured outcomes were immediate technical success rate, mortality, and morbidity. Median follow-up was 24.8 months (range, 0-15; mean, 8.2; standard deviation, 4 months).
The total endovascular repair of thoracoabdominal aortic aneurysm (TAAAs) and pararenal AAA (PAAAs) represents a hugely appealing less invasive approach. Major restrictions limiting its use are the anatomic requirements, the need for customized devices resulting in treatment delay, and the complex device sizing and procedural planning. [1] [2] [3] Therefore, there are subsets of patients that are considered unfit for traditional open aortic repair due to aortic cross-clamping and hemodynamic stress. In these patients, the hybrid approach, combining the surgical renovisceral debranching and the endovascular aneurysm exclusion, can bridge the gap between these two options, being readily available and reproducible. 4, 5 Despite the initial enthusiasm for the hybrid repair (HR), 6, 7 several series reported a 30-day mortality rates of 13% to 23%, which are similar to the outcomes after traditional open surgical repair. 8, 9 Most of the HR mortality was related to renovisceral dysfunctions. Although several factors are supposed to be involved in such dysfunction, the most important is definitely the ischemia time during the arterial anastomosis. 10 To reduce the renovisceral ischemia during multiple bypasses, a novel tool with sutureless endovascular anastomosis 11 was developed to allow a decreasing ischemic time during sequential bypass. Subsequently, with the same rationale grew up the Gore Hybrid Vascular Graft (GHVG; W. L. Gore and Associates, Flagstaff, Ariz), which is a novel expanded polytetrafluoroethylene (ePTFE) vascular prosthesis that includes a nitinol reinforced self-expanding section at one extremity that allows a "sutureless" endovascular anastomosis. The present study reports our initial experience with the GHVG used during renovisceral debranching in patients affected by TAAAs and PAAAs. The perioperative outcomes were immediate technical success rate, morbidity, and mortality. Immediate technical success was defined as the procedure being completed as intended. Intensive care unit length of stay (LOS), intubation duration, in-hospital LOS were also analyzed. Survival, primary patency, and secondary patency were estimated.
Adjunctive procedures related to visceral debranching during follow-up were recorded with their related outcomes (immediate technical success rate, perioperative mortality, and morbidity). Follow-up was calculated from the visceral debranching intervention. The follow-up protocol consisted of computed tomography angiography, laboratory testing, and clinical examination at 6 weeks, 3 and 6 months later, and yearly thereafter. Patients presenting with renal function impairment were monitored by native computed tomography and duplex ultrasound imaging of the aorta and target vessels.
Data analysis was performed using SPSS 16.0 software (IBM Corp, Armonk, NY). Mean and standard deviations (SDs) are reported for parametric data and absolute values and range for nonparametric data. Statistical significance was assigned at a two-sided P of <.05. Kaplan-Meier curves were used to estimate survival and patency. Median follow-up was 24.8 months (range, 0-15; mean, 8.2; SD, 4 months).
RESULTS
A total of 13 patients meet the inclusion criteria and were included in the study. Demographic and comorbidities are reported in the Table. Procedures were elective in 11 patients (85%) and nonelective in two (15%). One of these patients had a symptomatic descending thoracic aortic aneurysm and the remaining was a ruptured PAAA. The GHVG was used for 20 visceral vessels, with a mean of 1.54 vessels per patients. Six RAs (30%; 2 right and 4 left), 9 SMAs (45%), and 5 CTs (25%) were debranched.
Additional visceral vessels were addressed in nine (69%) of these patients with chimney/periscope graft 14, 15 (13 vessels), Viabahn Open Revascularization Technique 16 (2 vessels), and end-to-side anastomosis (2 vessels; Fig 1) .
Immediate technical success was achieved in all cases. Perioperative mortality was 15% (2 patients). One death occurred on postoperative day (POD) 2 caused by bowel ischemia and multiorgan failure secondary to multiple embolization. The SMA and CT were not debranched in this patient. The other perioperative death, on POD 18, was caused by bowel ischemia due to acute SMA occlusion. The SMA in this patient was addressed with an end-to-side anastomosis.
Perioperative complications occurred in three patients (23%), consisting in one patient each of renal hematoma (chimney/periscope related), respiratory insufficiency requiring prolonged intubation, and small bowel ischemia due to a GHVG thrombosis in the SMA. Mean intensive care unit LOS was 2.5 days (range, 0-9; SD, 3 days), intubation duration was 1.4 days (range, 0-6; SD, 2 days), and in-hospital LOS was 12 days (range, 2-35; SD, 10 days).
One adjunctive maneuver was performed in the patient who presented with small bowel ischemia caused by SMA-GHVG occlusion. The GHVG bypass occlusion was managed successfully by endovascular locoregional lysis. Estimated survival at 6 months was 85%. The estimated primary and secondary patency was 95% and 100%, respectively. Survival and patency curves are depicted in Figs 2 and 3 , respectively.
Debranching in 11 patients (85%) was followed by EVAR. EVAR was not performed in the remaining two patients due to death on PODs 2 and 18. The mean interval from visceral debranching with GHVG to aneurysm exclusion with EVAR was 2.5 months (range, 0-5; SD, 2 months). Both nonelective procedures were performed consecutively. 
DISCUSSION
Conflicting results of hybrid debranching strategy for TAAA and PAAA treatment led to criticism and ambiguity of this approach, despite initial enthusiasm.
17, 18 The systematic review by Moulakakis et al 19 analyzed 19 publications comprising 507 patients who underwent HR. This review reported a primary technical success of 96.2% (95% confidence interval [CI], 93.5%-98.2%) and visceral graft patency of 96.5% (95% CI, 95.2%-97.8%). The same report observed a pooled rate of 7.5% (95% CI, 5.0%-11.0%) for overall spinal cord ischemia symptoms, with an irreversible paraplegia rate of 4.5% (95% CI, 2.5%-7.0%). The pooled 30-day/in-hospital mortality rate was 12.8% (95% CI, 8.6%-17.0%). Despite these reported outcomes, the HR has demonstrated better results in some centers. 20 One of the most important issues related to the high mortality rate of the HR technique is that this operation remains technically demanding because of the extensive aortic exposure and prolonged interruption of aortic flow to the visceral branches. During the last decades, several new technical improvements focused attention on the reduction of ischemic time during the renovisceral anastomosis to reduce the risk of bowel ischemia and the global procedure time.
In our experience, since 2007, covered self-expanding stents are being used to perform "sutureless anastomoses" on renovisceral aortic branches during debranching procedures. This tool obviated the need for technically demanding vessel exposure and anastomoses, thereby reducing the duration of flow interruption and simplifying the performance of complex aortic repair.
During this time, the original Viabahn Open Revascularization Technique, with the transection of the target vessel, has been modified. The novel technique consists of placement of the Viabahn self expanding stent graft (W. L. Gore and Associates) in a Seldinger technique into the visceral arteries after surgical identification of the origin of these arteries. 21 Briefly, the Viabahn stent graft is passed through an ePTFE vascular graft, the visceral arterial wall is punctured, and a standard wire is placed. The Viabahn is then advanced (w2.5 cm) over the wire into the visceral artery, the vascular graft is placed against the arterial wall, and the stent graft is deployed. A balloon is inflated corresponding to the Viabahn that is positioned for half-length inside the artery and half-length inside the vascular graft. Finally, the arterial wall, the stent graft, and the vascular graft are fixed with a couple of stitches with Prolene (Ethicon, Somerville, NJ).
This modification already determined a reduced ischemic time from 11 minutes to <1 minute to perform a visceral anastomosis. The GHVG represents the natural evolution of this procedure, allowing a significant reduction of the global procedural time by using a single graft. The tubular heparin-bonded ePTFE graft is preconnected to the nitinol stent-reinforced section, guaranteeing in-line flow and avoiding flow turbulence. The device was released by Gore in 2012 in the European market and approved for hemodialysis access, lower limb bypass grafting, aortic arch debranching, and visceral revascularization. 22 Bornak et al 23 reported the first case of sutureless visceral artery revascularization using the GHVG in 2012. They described the treatment of a symptomatic TAAA involving the visceral segment and an infrarenal AAA. The patient was treated in a two-staged hybrid approach combining an endovascular repair of the infrarenal segment, followed by an open thoracic aortic aneurysm repair. The large visceral arteries were revascularized using GHVG and a gradual funneling technique with Dacron (DuPont, Wilmington, Del).
After this first reported patient, excluding the literature regarding hemodialysis access, two authors reported patients treated with GHVG in different aortic segments 24, 25 or in other districts. [26] [27] [28] The first large experience with the use of GHVG was recently reported by Chiesa et al 29 to address RAs during open TAAA repair. Their experience with 25 patients reported satisfactory results that are at least comparable to those of standard renal revascularization. This was the first study reporting GHVG outcomes in renovisceral debranching during TAAAs and PAAAs HR.
More recently Tsilimparis et al 30 reported their experience in 12 patients presenting challenging aortic disease and addressed with the GHVG in renovisceral arteries. In this series, with a median follow-up of 12 months, GHVG patency was 96%; moreover, using the GHVS resulted in a significant reduction of the time to perform the anastomosis compared with the standard anastomosis. Our limited experience of 13 patients showed that this technique was technically feasible in all the planned procedures, irrespective of renovisceral vessels anatomic location and quality, with good midterm results. In our reported experience, two patients died of bowel ischemia. The causes of death were due to multiple embolization in the first patient and to acute SMA occlusion in the second. It is important to note that only one RA was addressed in the first patient, and the SMA was revascularized in the second patient without GHVG but with end-to-side anastomosis.
At a median follow-up of 24.77 months, we reported one adjunctive procedure due to a GHVG-to-SMA occlusion that was successfully managed with locoregional lysis.
CONCLUSIONS
This limited series has to be considered, together with important limitations related to the small number of cases. However, technical feasibility and short-term patency rate of the GHVG for renovisceral debranching during staged hybrid open and endovascular procedures were satisfactory. This novel graft will represent an additional step forward in the challenge of perioperative visceral ischemia, allowing faster procedures. The midterm results are very promising, especially considering that this treatment option is chosen in patients considered unfit or at high-risk for conventional surgery or inappropriate for fenestrated/branched EVAR. 
